US 12,269,871 B2
Generation of a new site-specific monoclonal antibody for tau protein and its use as a tool in specific biomarkers for early detection of neurodegenerative diseases and pathologies
Leonardo Guzmán Martínez, Santiago (CL); Camila Calfío Painemal, Santiago (CL); Andrea González Zuñiga, Santiago (CL); Ricardo Maccioni Baraona, Santiago (CL); and Constanza Maccioni Romero, Santiago (CL)
Assigned to CORPORACIÓN CENTRO INTERNACIONAL DE BIOMEDICINA ICC, Santiago (CL)
Filed by CORPORACIÓN CENTRO INTERNACIONAL DE BIOMEDICINA ICC, Santiago (CL)
Filed on May 26, 2022, as Appl. No. 17/825,511.
Prior Publication US 2022/0389087 A1, Dec. 8, 2022
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); G01N 2800/2821 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A biomarker antibody for detection of neurodegenerative diseases and pathologies associated with tau protein, comprising:
a light chain variable region having at least 85 percent of sequence identity to SEQ ID NO: 2 comprising an LCDR1 set forth in SEQ ID NO: 4, an LCDR2 set forth in SEQ ID NO: 6, and an LCDR3 set forth in SEQ ID NO:8; and
a heavy chain variable region having at least 85 percent sequence identity to SEQ ID NO: 10 comprising an HCDR1 set forth in SEQ ID NO: 12, an HCDR2 set forth in SEQ ID NO: 14, and an HCDR3 set forth in SEQ ID NO:16,
wherein said antibody detects high molecular weight variants and a low molecular weight variants of tau protein, wherein the high molecular weight variants of tau protein are greater than 70 kDa and the low molecular weight variants of tau protein are less than 70 kDa.